Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from 68Ga-RGD PET/CT and 18F-FDG PET/CT

Hai Jeon Yoon; Keon Wook Kang; In Kook Chun; Nariya Cho; Seock Ah Im; Sunjoo Jeong; Song Lee; Kyeong Cheon Jung; Yun Sang Lee; Jae Min Jeong; Dong Soo Lee; June Key Chung; Woo Kyung Moon

doi:10.1007/s00259-014-2744-4

Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT

Hai Jeon Yoon, Keon Wook Kang, In Kook Chun, Nariya Cho, Seock Ah Im, Sunjoo Jeong, Song Lee, Kyeong Cheon Jung, Yun Sang Lee, Jae Min Jeong, Dong Soo Lee, June Key Chung, Woo Kyung Moon

Department of Nuclear Medicine

Research output: Contribution to journal › Article › peer-review

64 Scopus citations

Abstract

Purpose: Imaging biomarkers from functional imaging modalities were assessed as potential surrogate markers of disease status. Specifically, in this prospective study, we investigated the relationships between functional imaging parameters and histological prognostic factors and breast cancer subtypes. Methods: In total, 43 patients with large or locally advanced invasive ductal carcinoma (IDC) were analyzed (47.6±7.5 years old). ⁶⁸Ga- Labeled arginine-glycine-aspartic acid (RGD) and ¹⁸F- fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) were performed. The maximum and average standardized uptake values (SUV_max and SUV_avg) from RGD PET/CT and SUV_max and SUV_avg from FDG PET/CT were the imaging parameters used. For histological prognostic factors, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression was identified using immunohistochemistry (IHC) or fluorescent in situ hybridization (FISH). Four breast cancer subtypes, based on ER/PR and HER2 expression (ER/PR+,Her2-, ER/PR+,Her2+, ER/PR-,Her2+, and ER/PR-,Her2-), were considered. Results: Quantitative FDG PET parameters were significantly higher in the ER-negative group (15.88±8.73 vs 10.48±6.01, p=0.02 for SUV _max; 9.40±5.19 vs 5.92±4.09, p=0.02 for SUV _avg) and the PR-negative group (8.37±4.94 vs 4.79±3.93, p=0.03 for SUV_avg). Quantitative RGD PET parameters were significantly higher in the HER2-positive group (2.42±0.59 vs 2.90±0.75, p=0.04 for SUV_max; 1.60±0.38 vs 1.95±0.53, p=0.04 for SUV_avg) and showed a significant positive correlation with the HER2/CEP17 ratio (r=0.38, p=0.03 for SUV _max and r=0.46, p<0.01 for SUV_avg). FDG PET parameters showed significantly higher values in the ER/PR-,Her2- subgroup versus the ER/PR+,Her2- or ER/PR+,Her2+ subgroups, while RGD PET parameters showed significantly lower values in the ER/PR-,Her2- subgroup versus the other subgroups. There was no correlation between FDG and RGD PET parameters in the overall group. Only the ER/PR-,Her2- subgroup showed a significant positive correlation between FDG and RGD PET parameters (r=0.59, p=0.03 for SUV _max). Conclusion: ⁶⁸Ga-RGD and ¹⁸F-FDG PET/CT are promising functional imaging modalities for predicting biomarkers and molecular phenotypes in breast cancer patients.

Original language	English
Pages (from-to)	1534-1543
Number of pages	10
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	41
Issue number	8
DOIs	https://doi.org/10.1007/s00259-014-2744-4
State	Published - Aug 2014

Bibliographical note

Funding Information:
Acknowledgement This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health & Welfare, Republic of Korea (A070001 and A100716).

Keywords

Arginine-glycine-aspartic acid (RGD)
Estrogen receptor (ER)
Fluorodeoxyglucose (FDG)
Human epidermal growth factor receptor 2 (HER2)
Positron emission tomography (PET)
Progesterone receptor (PR)

Access to Document

10.1007/s00259-014-2744-4

Cite this

Yoon, H. J., Kang, K. W., Chun, I. K., Cho, N., Im, S. A., Jeong, S., Lee, S., Jung, K. C., Lee, Y. S., Jeong, J. M., Lee, D. S., Chung, J. K., & Moon, W. K. (2014). Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 41(8), 1534-1543. https://doi.org/10.1007/s00259-014-2744-4

@article{7e11a19795d44e41984fc1b5306c46b8,

title = "Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from 68Ga-RGD PET/CT and 18F-FDG PET/CT",

abstract = "Purpose: Imaging biomarkers from functional imaging modalities were assessed as potential surrogate markers of disease status. Specifically, in this prospective study, we investigated the relationships between functional imaging parameters and histological prognostic factors and breast cancer subtypes. Methods: In total, 43 patients with large or locally advanced invasive ductal carcinoma (IDC) were analyzed (47.6±7.5 years old). 68Ga- Labeled arginine-glycine-aspartic acid (RGD) and 18F- fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) were performed. The maximum and average standardized uptake values (SUVmax and SUVavg) from RGD PET/CT and SUVmax and SUVavg from FDG PET/CT were the imaging parameters used. For histological prognostic factors, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression was identified using immunohistochemistry (IHC) or fluorescent in situ hybridization (FISH). Four breast cancer subtypes, based on ER/PR and HER2 expression (ER/PR+,Her2-, ER/PR+,Her2+, ER/PR-,Her2+, and ER/PR-,Her2-), were considered. Results: Quantitative FDG PET parameters were significantly higher in the ER-negative group (15.88±8.73 vs 10.48±6.01, p=0.02 for SUV max; 9.40±5.19 vs 5.92±4.09, p=0.02 for SUV avg) and the PR-negative group (8.37±4.94 vs 4.79±3.93, p=0.03 for SUVavg). Quantitative RGD PET parameters were significantly higher in the HER2-positive group (2.42±0.59 vs 2.90±0.75, p=0.04 for SUVmax; 1.60±0.38 vs 1.95±0.53, p=0.04 for SUVavg) and showed a significant positive correlation with the HER2/CEP17 ratio (r=0.38, p=0.03 for SUV max and r=0.46, p<0.01 for SUVavg). FDG PET parameters showed significantly higher values in the ER/PR-,Her2- subgroup versus the ER/PR+,Her2- or ER/PR+,Her2+ subgroups, while RGD PET parameters showed significantly lower values in the ER/PR-,Her2- subgroup versus the other subgroups. There was no correlation between FDG and RGD PET parameters in the overall group. Only the ER/PR-,Her2- subgroup showed a significant positive correlation between FDG and RGD PET parameters (r=0.59, p=0.03 for SUV max). Conclusion: 68Ga-RGD and 18F-FDG PET/CT are promising functional imaging modalities for predicting biomarkers and molecular phenotypes in breast cancer patients.",

keywords = "Arginine-glycine-aspartic acid (RGD), Estrogen receptor (ER), Fluorodeoxyglucose (FDG), Human epidermal growth factor receptor 2 (HER2), Positron emission tomography (PET), Progesterone receptor (PR)",

author = "Yoon, {Hai Jeon} and Kang, {Keon Wook} and Chun, {In Kook} and Nariya Cho and Im, {Seock Ah} and Sunjoo Jeong and Song Lee and Jung, {Kyeong Cheon} and Lee, {Yun Sang} and Jeong, {Jae Min} and Lee, {Dong Soo} and Chung, {June Key} and Moon, {Woo Kyung}",

note = "Funding Information: Acknowledgement This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health & Welfare, Republic of Korea (A070001 and A100716).",

year = "2014",

month = aug,

doi = "10.1007/s00259-014-2744-4",

language = "English",

volume = "41",

pages = "1534--1543",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer Verlag",

number = "8",

}

Yoon, HJ, Kang, KW, Chun, IK, Cho, N, Im, SA, Jeong, S, Lee, S, Jung, KC, Lee, YS, Jeong, JM, Lee, DS, Chung, JK & Moon, WK 2014, 'Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT', European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 8, pp. 1534-1543. https://doi.org/10.1007/s00259-014-2744-4

Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT. / Yoon, Hai Jeon; Kang, Keon Wook; Chun, In Kook et al.
In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 41, No. 8, 08.2014, p. 1534-1543.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from 68Ga-RGD PET/CT and 18F-FDG PET/CT

AU - Yoon, Hai Jeon

AU - Kang, Keon Wook

AU - Chun, In Kook

AU - Cho, Nariya

AU - Im, Seock Ah

AU - Jeong, Sunjoo

AU - Lee, Song

AU - Jung, Kyeong Cheon

AU - Lee, Yun Sang

AU - Jeong, Jae Min

AU - Lee, Dong Soo

AU - Chung, June Key

AU - Moon, Woo Kyung

N1 - Funding Information: Acknowledgement This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health & Welfare, Republic of Korea (A070001 and A100716).

PY - 2014/8

Y1 - 2014/8

N2 - Purpose: Imaging biomarkers from functional imaging modalities were assessed as potential surrogate markers of disease status. Specifically, in this prospective study, we investigated the relationships between functional imaging parameters and histological prognostic factors and breast cancer subtypes. Methods: In total, 43 patients with large or locally advanced invasive ductal carcinoma (IDC) were analyzed (47.6±7.5 years old). 68Ga- Labeled arginine-glycine-aspartic acid (RGD) and 18F- fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) were performed. The maximum and average standardized uptake values (SUVmax and SUVavg) from RGD PET/CT and SUVmax and SUVavg from FDG PET/CT were the imaging parameters used. For histological prognostic factors, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression was identified using immunohistochemistry (IHC) or fluorescent in situ hybridization (FISH). Four breast cancer subtypes, based on ER/PR and HER2 expression (ER/PR+,Her2-, ER/PR+,Her2+, ER/PR-,Her2+, and ER/PR-,Her2-), were considered. Results: Quantitative FDG PET parameters were significantly higher in the ER-negative group (15.88±8.73 vs 10.48±6.01, p=0.02 for SUV max; 9.40±5.19 vs 5.92±4.09, p=0.02 for SUV avg) and the PR-negative group (8.37±4.94 vs 4.79±3.93, p=0.03 for SUVavg). Quantitative RGD PET parameters were significantly higher in the HER2-positive group (2.42±0.59 vs 2.90±0.75, p=0.04 for SUVmax; 1.60±0.38 vs 1.95±0.53, p=0.04 for SUVavg) and showed a significant positive correlation with the HER2/CEP17 ratio (r=0.38, p=0.03 for SUV max and r=0.46, p<0.01 for SUVavg). FDG PET parameters showed significantly higher values in the ER/PR-,Her2- subgroup versus the ER/PR+,Her2- or ER/PR+,Her2+ subgroups, while RGD PET parameters showed significantly lower values in the ER/PR-,Her2- subgroup versus the other subgroups. There was no correlation between FDG and RGD PET parameters in the overall group. Only the ER/PR-,Her2- subgroup showed a significant positive correlation between FDG and RGD PET parameters (r=0.59, p=0.03 for SUV max). Conclusion: 68Ga-RGD and 18F-FDG PET/CT are promising functional imaging modalities for predicting biomarkers and molecular phenotypes in breast cancer patients.

AB - Purpose: Imaging biomarkers from functional imaging modalities were assessed as potential surrogate markers of disease status. Specifically, in this prospective study, we investigated the relationships between functional imaging parameters and histological prognostic factors and breast cancer subtypes. Methods: In total, 43 patients with large or locally advanced invasive ductal carcinoma (IDC) were analyzed (47.6±7.5 years old). 68Ga- Labeled arginine-glycine-aspartic acid (RGD) and 18F- fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) were performed. The maximum and average standardized uptake values (SUVmax and SUVavg) from RGD PET/CT and SUVmax and SUVavg from FDG PET/CT were the imaging parameters used. For histological prognostic factors, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression was identified using immunohistochemistry (IHC) or fluorescent in situ hybridization (FISH). Four breast cancer subtypes, based on ER/PR and HER2 expression (ER/PR+,Her2-, ER/PR+,Her2+, ER/PR-,Her2+, and ER/PR-,Her2-), were considered. Results: Quantitative FDG PET parameters were significantly higher in the ER-negative group (15.88±8.73 vs 10.48±6.01, p=0.02 for SUV max; 9.40±5.19 vs 5.92±4.09, p=0.02 for SUV avg) and the PR-negative group (8.37±4.94 vs 4.79±3.93, p=0.03 for SUVavg). Quantitative RGD PET parameters were significantly higher in the HER2-positive group (2.42±0.59 vs 2.90±0.75, p=0.04 for SUVmax; 1.60±0.38 vs 1.95±0.53, p=0.04 for SUVavg) and showed a significant positive correlation with the HER2/CEP17 ratio (r=0.38, p=0.03 for SUV max and r=0.46, p<0.01 for SUVavg). FDG PET parameters showed significantly higher values in the ER/PR-,Her2- subgroup versus the ER/PR+,Her2- or ER/PR+,Her2+ subgroups, while RGD PET parameters showed significantly lower values in the ER/PR-,Her2- subgroup versus the other subgroups. There was no correlation between FDG and RGD PET parameters in the overall group. Only the ER/PR-,Her2- subgroup showed a significant positive correlation between FDG and RGD PET parameters (r=0.59, p=0.03 for SUV max). Conclusion: 68Ga-RGD and 18F-FDG PET/CT are promising functional imaging modalities for predicting biomarkers and molecular phenotypes in breast cancer patients.

KW - Arginine-glycine-aspartic acid (RGD)

KW - Estrogen receptor (ER)

KW - Fluorodeoxyglucose (FDG)

KW - Human epidermal growth factor receptor 2 (HER2)

KW - Positron emission tomography (PET)

KW - Progesterone receptor (PR)

UR - http://www.scopus.com/inward/record.url?scp=84905565621&partnerID=8YFLogxK

U2 - 10.1007/s00259-014-2744-4

DO - 10.1007/s00259-014-2744-4

M3 - Article

C2 - 24652232

AN - SCOPUS:84905565621

SN - 1619-7070

VL - 41

SP - 1534

EP - 1543

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 8

ER -